Expression of CD44 and CD35 during normal and myelodysplastic erythropoiesis

Leuk Res. 2015 Mar;39(3):361-70. doi: 10.1016/j.leukres.2014.12.009. Epub 2014 Dec 24.

Abstract

Erythroid dysplasia is a common feature of myelodysplastic syndromes (MDS). Currently available information about the immunophenotypic features of normal and dysplastic erythropoiesis is scarce and restricted to relatively few markers. Here we studied the expression of CD117, CD35 and CD44 throughout the normal (n=16) and dysplastic (n=48) bone marrow erythroid maturation. CD35 emerged as an early marker of CD34(+) erythroid-committed precursors, which is expressed before CD105 and remains positive thereafter. MDS patients (with and without morphologic dyserythropoiesis) displayed overall increased expression of CD44, associated with slight alterations on CD35 expression, suggesting that phenotypic alterations in MDS may precede morphologic dysplasia. In turn, MDS patients with anemia showed increased expression of CD117.

Keywords: CD117; CD35; CD44; Erythroid maturation; Erythroid precursor; Myelodysplastic syndrome.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers, Tumor / metabolism*
  • Bone Marrow / metabolism*
  • Bone Marrow / pathology
  • Case-Control Studies
  • Erythroid Precursor Cells / metabolism*
  • Erythroid Precursor Cells / pathology
  • Erythropoiesis*
  • Female
  • Flow Cytometry
  • Follow-Up Studies
  • Humans
  • Hyaluronan Receptors / metabolism*
  • Immunophenotyping
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / metabolism*
  • Myelodysplastic Syndromes / pathology
  • Neoplasm Staging
  • Phenotype
  • Prognosis
  • Receptors, Complement 3b / metabolism*

Substances

  • Biomarkers, Tumor
  • CD44 protein, human
  • CR1 protein, human
  • Hyaluronan Receptors
  • Receptors, Complement 3b